TY  - JOUR
A1  - Rauert-Wunderlich, Hilka
A1  - Berberich, Ingolf
A1  - Rosenwald, Andreas
A1  - Rudelius, Martina
T1  - CD40L mediated alternative NF kappa B-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
JF  - Cell Death & Disease
N2  - Drug resistance is a significant obstacle in cancer treatment and therefore a frequent subject of research. Developed or primary resistance limits the treatment success of inhibitors of the B cell receptor (BCR) pathway in mantle cell lymphoma (MCL) patients. Recent research has highlighted the role of the nuclear factor-kappa B (NF kappa B) pathway in the context of resistance to BCR inhibitors in MCL. In this study, we analyzed the dependency of MCL cell lines on NF kappa B signaling and illustrated the ability of CD40L to activate the alternative NF kappa B pathway in MCL. This activation leads to independency of classical NF kappa B signaling and results in resistance to BCR inhibitors. Therefore, ligands (such as CD40L) and their activation of the alternative NF kappa B pathway have a major impact on the drug response in MCL. Furthermore, this study indicates a protective role for cells expressing specific ligands as microenvironmental niches for MCL cells and underlines the significance of therapeutically targeting alternative NF kappa B signaling in MCL.
KW  - Bruton Tyrosine Kinase
KW  - Tumor Microenvironment
KW  - Targeted Therapies
KW  - Ibrutinib
KW  - Pathway
KW  - Malignancies
KW  - Activation
KW  - Ligand
KW  - Proliferation
KW  - PCI-32765
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225027
IS  - 9
ER  -